GLP-3 RT – 30 mg Dosage Protocol

What is GLP-3 RT?

GLP-3 RT (also referenced in research settings as RT30 or GL-3 RT) is a next-generation synthetic triple-receptor agonist peptide engineered to interact with three metabolic pathways simultaneously: GLP-1, GIP, and the Glucagon receptor (GCGR). By combining incretin mimicking actions with glucagon receptor engagement, it represents a brand-new frontier in advanced metabolic and obesity research models. GLP-3 RT remains an experimental unimolecular tri-agonist and is currently being studied strictly for laboratory research purposes.

Potential Benefits

Decreases appetite and caloric intake while inhibiting weight gain models
Actively drives the cellular conversion of white fat to brown fat (thermogenesis)
Accelerates resting energy expenditure and whole-body basal metabolic rate
Enhances glycemic control, insulin sensitivity, and pancreatic beta-cell function
Lowers fasting insulin, fasting glucose, and overall hemoglobin A1c markers
Reduces hepatic lipid accumulation, targeting fatty liver and triglyceride markers
Decreases baseline leptin levels while simultaneously increasing leptin sensitivity

GLP-3 RT 30 mg Dosage Protocol

Vial Size: 30 mg
Reconstitution: 3 mL Bacteriostatic Water
Concentration: 10 mg/mL (10,000 mcg/mL)
Administration: Subcutaneous Injection
Frequency: Once Weekly

Dosage Chart

Weeks

Weekly Dose

Syringe Units (100-Unit / 1mL Syringe)

1–4

2,000 mcg (2 mg)

20 Units

5–8

4,000 mcg (4 mg)

40 Units

9–12

6,000 mcg (6 mg)

60 Units

13–16

8,000 mcg (8 mg)

80 Units

17+

10,000 mcg (10 mg)

100 Units (Full Syringe)

Reconstitution

Add 3 mL of bacteriostatic water to the 30 mg vial.
Inject the water slowly down the inside glass wall of the vial.
Gently swirl until the lyophilized powder is fully dissolved.
Do not shake vigorously to avoid structural degradation.
Refrigerate immediately after mixing.

Storage

Before reconstitution: Store frozen at −20°C (−4°F) or below for optimal long-term stability.
After reconstitution: Store refrigerated at 2–8°C (36–46°F).
Use within 7 days post-mixing for best chemical consistency and stability metrics.

Injection Guide

Inject subcutaneously once weekly. Common laboratory testing injection sites include:

Abdomen (avoiding the immediate navel area)
Upper thighs
Back of upper arms

Research Note: Rotate the injection sites regularly across test subjects to minimize localized tissue irritation.

Research Summary

GLP-3 RT represents a significant evolution beyond traditional single-receptor (GLP-1) and dual-receptor (GLP-1/GIP) compound structures. The integration of the third pathway—glucagon receptor agonism—introduces a thermogenic component that enhances resting energy expenditure and optimizes adipose tissue reductions. While preclinical evaluations and phase 2 trial data report significant improvements in body mass index, glucose homeostasis, and hepatic steatosis reductions, extensive further human trial validation is required to establish complete safety, long-term toxicological profiles, and efficacy baselines.

Disclaimer

This information is provided for educational and scientific laboratory purposes only. GLP-3 RT is an investigational triple-receptor agonist peptide and is not approved to diagnose, treat, cure, or prevent any disease or medical condition. It is strictly not for human consumption, veterinary applications, or therapeutic deployment. Always consult a qualified professional before handling research chemicals.